Dr. Matheu founded Prellis Biologics in October 2016 to solve a systemic problem in bioprinting technologies: the inability of other bioprinting methods to match tissue resolution and the speed necessary to build human tissues and organs. Drawing on her academic background in Physiology, Biophysics, and Immunology, Melanie saw an opportunity to further the status quo of functional tissue development and designed the first ultrafast high-resolution mutli-photon bioprinting system. Dr. Matheu is dedicated to pushing technological limits to achieve the manufacturing of transplantable human tissues and enabling rapid, accurate drug development. Today, Prellis is commercializing its first tissue: human lymph node organoids for rapid human antibody discovery and therapeutic testing.